SynthesisMedicine2025
Surfactant protein A as an important biomarker for interstitial lung disease in the assessment of occurrence, progression, acute exacerbation, and mortality: A systematic review and meta-analysis.
Synthesis in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundInterstitial lung disease (ILD) is a large group of heterogeneous pulmonary disorders with complex etiologies. Noninvasive biomarkers serve as important tools for diagnosis and predicting prognosis of ILD. There is no comprehensive evidence for the clinical value of serum surfactant protein A (SP-A) in ILD population.
methodsA systematical search was performed in PubMed, Web of Science, Cochrane Library, Embase and Scopus for English literatures published before May 1, 2024. The Newcastle-Ottawa scale was use for quality assessment of literatures. The weighted mean difference of serum SP-A in ILD with different disease states was summarized and analyzed. Sensitivity analysis was proceeded by sequentially excluding 1 study at a time and merging the remaining studies. Publication bias was judged by funnel plots, Egger's test and trim-and-fill method.
resultsA total of 22 studies comprising 2573 ILD patients were included in this meta-analysis. The results revealed that serum SP-A levels were significantly higher in ILD group compared to control group (weighted mean difference [WMD] = 29.82 ng/mL, 95% confidence interval [CI]: 17.15-42.59), serum SP-A levels of ILD patients in progression group were statistically higher than stable group (WMD = 18.36 ng/mL, 95% CI: 6.13-30.59), acute exacerbation group were significantly higher than non-acute exacerbation group (WMD = 16.47 ng/mL, 95% CI: 6.68-26.26), death group were distinctly higher than survival group (WMD = 23.63 ng/mL, 95% CI: 18.73-28.53) respectively.
conclusionElevated serum SP-A emerges as a pivotal noninvasive biomarker for assessing disease states and prognosis in ILD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.